Influenza vaccines have cut people’s risk of being hospitalized from the disease by approximately half, according to a new CDC report.
CDC's director has signed off on the widespread use of updated COVID-19 vaccines, which are intended to better align with SARS-CoV-2 strains now in circulation.
An FDA advisory panel unanimously agreed that oral phenylephrine is not effective at relieving nasal stuffiness. The decision, voted on during FDA’s Nonprescription Drugs Advisory Committee meeting, could result in the removal of oral formulations of phenylephrine.
Results from a new study published in JAMA find that among patients with major depressive disorder (MDD), a single 25-mg dose of psilocybin led to a steady reduction in depressive symptoms and helped improve psychosocial functioning. The goal of the research was to examine the safety and efficacy of using psilocybin in patients with MDD.
The popular GLP-1 receptor agonists, originally approved for T2D, may also be beneficial for patients with T1D—at least, that’s what findings from a small study published in NEJM imply.